Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug ...
Pfizer said on Tuesday that it has reached settlement agreements with three generic manufacturers — Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd. — resolving patent-infringement lawsuits over ...
BridgeBio (BBIO) rose 2.9% after a court filing appeared to indicate a settlement in a generic patent case over Pfizer's (PFE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results